Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well venetoclax and ibrutinib work in treating participants
with chronic lymphocytic leukemia and have developed genetic mutations after previously being
treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.